clinical practice, healthcare systems and available resources, Asian clinicians require guidance from experts on how to achieve treatment goals 
| MATERIAL S AND ME THODS
A working group was convened to develop a set of APLAR axial SpA treatment recommendations that were practical and relevant to the needs of patients and clinicians in the Asia-Pacific region. All member national organizations of APLAR were invited to nominate a representative to join the group. The final group was, thus, comprised entirely of representatives from the national member organizations of APLAR. In the first meeting, members of the group developed 24 clinically important questions related to the treatment of axial SpA as the basis for the literature search.
Search strategies were developed for each question using medical subject headings for MEDLINE, and adapted for other databases.
MEDLINE was searched through PubMed, EMBASE and the Cochrane
Library from January 2000 to December 2016, limited to English language articles. Following completion of the search, the collected articles per question were assigned to a working group member for review.
The evidence was presented in summary-of-findings tables to the working group over the subsequent meetings, over the period of November 2016 to November 2017. At the second meeting, the participants discussed the quality of evidence and started to draft the recommendations. The quality of evidence was determined for all outcomes of interest, based on the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The strength of a recommendation was described as "strongly in favor", "conditionally in favor", "conditionally against" and "strongly against" (Table 1) . 21 Four categories for the quality of evidence were "very low", "low", "moderate" and "high" (Table 2) 21,22 Some recommendations were not graded because of lack of eligible evidence to support them.
Such statements were still included to represent practical guidance for common important clinical situations. Supplementary evidence was presented during the 3rd meeting, with the draft recommendations reworded and refined based on the members' evolving understanding of the implications of the enlarging evidence base. At the conclusion of the 3rd meeting a final set of 14 draft recommendations was agreed upon which covered key aspects of the management of axial SpA.
A voting group was then convened, comprised of members of APLAR's Axial SpA Special Interest Group. The consensus process was a modification of the Delphi technique: members of the voting group were asked to rate their agreement with each recommendation on a 5-point Likert scale (ie: 5, strongly agree; 4, agree; 3, neither agree nor disagree; 2, disagree; 1 strongly disagree); agreement by 75% of total voting members (ie proportion of members indicating "strongly agree" plus proportion indicating "agree" equals 75%)
was previously defined as achieving consensus on a statement.
Consensus was achieved on all statements in the first voting Feedback from the respondents was used to finalize the recommendations and inform supporting text.
| RE SULTS
The recommendations are presented with their level of agreement and overall grade. Some recommendations are accompanied by supporting statements for additional guidance. Each recommendation is followed by a discussion of the evidence and rationale supporting its inclusion. Table 3 We conditionally recommend, prior to starting bDMARD, to screen for TB, HBV, HCV and human HIV (in high-risk populations). Treatment for latent TB (according to local guidelines) and pre-emptive therapy for chronic hepatitis B infection are also conditionally recommended Very low
8
We strongly recommend using a TNF inhibitor as the initial bDMARD treatment Very low
9
We conditionally recommend using TNF inhibitor monoclonal antibodies over fusion protein in patients with features beyond arthritis and enthesitis, such as concomitant inflammatory bowel disease, recurrent anterior uveitis, and psoriasis.
Low

10
In adults with persistent active axial SpA despite an adequate trial of the 1st TNF inhibitor for at least 12 weeks, we conditionally recommend treatment with another TNF inhibitor or secukinumab Very low
11
We conditionally recommend continuing bDMARD therapy in patients who respond well to treatment, but a reduced dose or increased interval may be considered in patients in sustained remission RCTs, in which program durations ranged from 8 weeks to 7 months, and from an observational study of a 6-week, home-based exercise program. The trials showed improvements in function, disease activity and pain. [25] [26] [27] [28] [29] [30] [31] Cardiovascular risk benefits were also confirmed.
30
As in other parts of the world, management of axial SpA in the Asia-Pacific region involves a multimodal approach that combines exercise and physical therapy with pharmacological therapy to meet treatment goals. Although the efficacy of exercise and physical therapy in improving axial SpA symptoms and disabilities is well documented, the panel judged the evidence of benefits to be marginal, and the quality of evidence was rated as low based mainly on risk of bias across studies. Also, the cost of supervised therapy and access to exercise programs, and availability of physical therapists, may vary across countries in the Asia-Pacific, which justified the inclusion of a conditional recommendation.
Smoking cessation is strongly encouraged in patients with axial
SpA (Vote 100% agreement; grade of evidence low).
Quitting smoking is particularly relevant for patients with SpA because smoking is associated with higher levels of disease activity and disability in patients with axial SpA who were smokers, compared with non-smokers. 32 In addition, it has a negative influence on bronchopulmonary and cardiovascular outcomes in SpA 33 and is a major risk factor for cancers of the lung and multiple other sites. 34 Smoking cessation may be beneficial, based on the review of five cross-sectional studies that linked smoking with poorer treatment outcomes such as disease activity, quality of life and structural progression. [35] [36] [37] [38] [39] Although there are no interventional studies to confirm the benefits of quitting smoking on axial SpA signs and symptoms or on cardiovascular endpoints in patients with SpA, the group agreed to issue a strong recommendation against smoking to emphasize the benefits of quitting on general health and the potential benefits in axial SpA. This statement is highly relevant to the Asia-Pacific region, which has seen a rise in tobacco use through the years. This rise in smoking is more in developing countries of the region which lack quality tobacco control programs, and in these countries, a link between smoking and a high risk of death from cardiovascular disease, cancer and respiratory disease has been shown. • We strongly recommend that treatment with NSAIDs should be individualized according to the patient's response to treatment and their risk for major cardiovascular events, gastrointestinal (GI) complications or renal disease (Grade of evidence moderate).
• We strongly recommend that the duration of treatment should depend on the balance between the benefits of treatment and the risk of adverse events (Grade of evidence moderate).
We found moderate-to high-quality evidence for the efficacy of not be inferior to continuous use. 47, 48 The combined evidence was judged to have high risk of bias and inconsistency. However, the panel included a conditional recommendation for continuous use to highlight the potential benefit for patients at high risk of structural damage.
In its 2015 guidelines, the ACR/SPARTAN/SAA strongly recommends treatment with NSAIDs over no treatment for adults with active AS. Continuous treatment with NSAIDs was conditionally recommended over on-demand treatment with NSAIDs. There was no recommendation about the specific duration of NSAID treatment.
18
In the 2016 ASAS/EULAR update of the guidelines for the management of axial SpA, the use of NSAIDs as first-line drug treatment up to the maximum dose is strongly recommended for patients suffering from pain and stiffness. For people who respond well, continuous use of NSAIDs is recommended. There was also no mention of the specific duration for which NSAIDs should be given.
19
The panel analyzed the evidence for duration of NSAID treatment as well as NSAID safety. Based on moderate-to high-quality evidence, treatment with NSAIDs (traditional NSAIDs and COX-2i) for up to 52 weeks was effective in reducing pain, controlling disease activity, and improving function among patients with axial SpA. [41] [42] [43] Trial duration ranged from 2 weeks to 52 weeks. One RCT had a double-blind extension after the original 6-week trial for up to 52 weeks, in which patients remained in the original treatment arm, and showed comparable results as after the 6-week period. 41 Two RCTs showed that the mean BASFI score was 12.72 points lower (95% CI 9.83-15.61) in the intervention group after 6 weeks of treatment with NSAIDs.
18
Regarding safety, moderate-to high-quality evidence from a meta-analysis showed that the use of NSAIDs increased the risk of major vascular events (myocardial infarction [MI], stroke, or death), and GI complications (bleeding, perforation or obstruction). 50 The meta-analysis of individual participant data from a total of 297 trials compared COX-2i with placebo in terms of major vascular events (fatal and non-fatal MI; fatal or non-fatal stroke; mortality) and GI complications. Annual event rates for all the outcomes among patients randomized to COX-2i were very low: major vascular events 1.15% per year; MI or coronary heart disease death 0.63% per year;
upper GI complications 0.38% per year; and GI bleed 0.33% per year.
50
While the risks for major vascular events and GI complications were increased, the magnitude of risk can be estimated per NSAID and used to guide treatment decisions. Given these findings, the group formed consensus around the principle that treatment with 
Supporting statements
• The definition of active disease is considered to be BASDAI ≥4 or
Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP ≥2.1, especially in those with elevated CRP or active inflammation on MRI (Not graded).
• The evidence shows that bDMARD therapy is effective in achieving good disease control in the long term, with a reduction in complications, for patients with axial SpA (Not graded).
The MAXIMA survey of management practices, which involved rheumatologists from around the globe (including the Asia-Pacific region), reported that clinicians typically prescribed a round of 1-2 Significantly more patients achieved ASAS40 responses (66.9% aggregate). 73, 74 There were no head-to-head comparisons between different biologic agents. There were no safety concerns, and adverse events were similar in both the treatment and placebo groups.
Cross-over designs meant that RCT data were mostly limited to short-term efficacy and follow-up of up to 6 months. Long-term followup was available for seven major studies, in cohorts of 16-255 patients, for all biologics except secukinumab. 85, 86 Follow-up periods varied from 96 weeks to 8 years. Overall, in long-term follow-up studies, between ~50% and 70% of patients were able to remain on an anti-TNF therapy for 5-8 years. Infliximab had the longest follow-up and lowest retention. 85 Sustained response to therapy was seen in approximately 2/3 of patients over these long periods of follow up. Serious adverse events were rare, with the most common being infections. Etanercept was associated with more cases of recurrent uveitis. with HIV. 94 Given the high prevalence of these infectious diseases in the region, and the concern for risk of infection with DMARDs, the group considered it imperative to review the evidence on infections in the DMARD-receiving population. Notably, the majority of studies reviewed were focused on non-Asian subjects; clinical studies in Asian patients are warranted.
A recent meta-analysis evaluating the safety profile of TNFi included 19 RCTs involving 8320 patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or AS. 95 The occurrence of TB was reported as 0.6% in the treatment groups (32 events in 5339 patients),
while no event was reported in the control groups (2981 patients). 8. We strongly recommend using a TNF inhibitor as the initial bD-MARD treatment (Vote 100% agreement; grade of evidence very low).
• The choice of TNF inhibitor may be influenced by availability, cost, mode of delivery and patient preference (Not graded).
• Secukinumab is a suitable alternative if TNF inhibitors are contraindicated or unavailable, except in the setting of concomitant inflammatory bowel disease (Not graded).
The effectiveness of bDMARDs (TNFi and secukinumab) in axial
SpA that have failed NSAID treatment has been already discussed.
Head-to-head data exists for infliximab versus etanercept for AS from a 2-year, open-label, randomized study, which may help inform clinicians on which bDMARD to use. However, the study found no differences between groups in point estimates of BASDAI or BASFI at 2 years (no CIs reported). The study was judged as having high risk of bias, further suggesting no difference in efficacy.
111
No head-to-head data comparing other TNFi, or TNFi versus other bDMARDs with different targets, were found. Indirect analyses have not suggested a difference in efficacy within the TNFi class 112, 113 or between TNFi and secukinumab in AS. 115 There are no comparative data for interventions with other mechanisms of action, including the Janus-activated kinase inhibitors, despite preliminary evidence for the efficacy of tofacitinib. 116 Existing RCT data do not provide evidence for the efficacy of therapies that target the interleukin (IL)-23 pathway in axial SpA. 117, 118 Efficacy data from RCTs for TNFi versus placebo exist for nr-axial SpA but currently there are no comparative data. An indirect comparison did not find any difference in efficacy between TNFi.
119
With the current evidence for the effectiveness of TNFi, especially for continued use over several years, the group recommends this class of drugs be used in preference as a first-line bDMARD.
The choice of TNFi will depend on factors such as accessibility to the drug -especially in the Asia-Pacific region where reimbursement options vary across countries -and patient preferences.
120
The novel bDMARD secukinumab, an IL-17A inhibitor, may be an alternative in patients with a contraindication to TNFi. 121 Adverse events in Crohn's disease are common with secukinumab, 122 so it is not advised for use in axial SpA with IBD.
9. We conditionally recommend using TNFi monoclonal antibodies over fusion protein in patients with features beyond arthritis and enthesitis, such as concomitant IBD, recurrent anterior uveitis, and psoriasis (Vote 100%; grade of evidence low).
Supporting statements
• For patients with psoriasis, secukinumab may be preferred (Not graded).
• The concomitant use of csDMARD with TNFi in patients with axial SpA does not increase clinical effectiveness and is thus, not recommended (Not graded).
• In patients who do not respond to a TNFi, especially if they have peripheral arthritis, concomitant csDMARD may be considered (Not graded).
Results from mixed-quality evidence (clinical trials and metaanalyses) suggest that lower rates of uveitis flares in AS were asso- Consortium of Canada, switching to another TNFi should be considered after initial TNFi failure. 18, 19, 138 ASAS/EULAR and this working group considered the evidence from an RCT that showed secukinumab to be superior to placebo in improving ASAS20 in TNFi-intolerant patients. 139, 140 Overall very low-quality evidence as cited by the guidelines led to the present conditional recommendation by the panel. Various potential durations for an "adequate trial" were proffered and discussed before consensus was formed for a period of at least 12 weeks, that is, the standard duration of clinical trials assessing TNFi efficacy.
11. We conditionally recommend continuing bDMARD therapy in patients who respond well to treatment, but a reduced dose or increased interval may be considered in patients in sustained remission (Vote 100% agreement; grade of evidence low).
Three observational studies showed that discontinuation of TNFi led to flares in most of the patients with early axial SpA or AS. 69, 141, 142 When the drug is continued but with a reduced dose, remission can be maintained: a small RCT showed that patients remained in remission even with a reduced dose of etanercept (50 mg every other week or 50 mg weekly). 143 Another study showed that etanercept 25 mg weekly was less effective at maintaining treatment response in the step-down phase, although about half of the patients maintained treatment response with this dose. 144 The panel debated the definition of "sustained remission", after noting marked heterogeneity in trials where some included patients who were in remission for only a few months and others as long as 3 years. Given that there is no clear definition of "sustained remission" in widespread use and the overall quality of evidence is poor, the treating clinician should consider reduction of dose or increase of dosing interval after discussion with the patient.
12. Special situations. (a) For patients with axial SpA in whom disease cannot otherwise be controlled, we conditionally recommend continuing TNFi throughout pregnancy. (b) While biologics can be used in renal failure, caution is advised and treatment considered on a caseto-case basis (Vote 100% agreement; grade of evidence very low).
Supporting statement
• There is no evidence of an increased risk of malignancy in patients receiving long-term biologic therapy, particularly TNFi. However, caution is advised in populations at high risk of skin cancers (Not graded).
There are some concerns on the use of TNFi and biologics for axial SpA with some concomitant conditions. Most of the data on pregnancy and lactation were related to TNFi use (1 for tofaticinib) from observational studies. 145, 146 Large monoclonal antibodies do not cross the placenta in the first trimester, as they rely on active transport across placenta via Fc receptors on trophoblasts which only develop by week 14. 145 Certolizumab lacks an Fc receptor and therefore has a theoretical advantage as it does not cross the placenta; therefore it could be safe to use beyond week 14. Although the number of live births was reduced in those patients who had received TNFi, more patients in this group had opted for termination of pregnancy. TNFi was detected in breast milk, but long-term adverse outcomes on the child are unknown.
Malignancy rates (all cancers, excluding non-melanoma skin cancers) were evaluated in both randomized controlled trials and observational studies. 73, 76, 78, 79, 83, 116, 121, 161, 162 Although there was no evidence of increased malignancy in the randomized trials, exclusion criteria were strict, and follow-up was of short duration. 73, 76, 79, 83, 116, 121, [161] [162] [163] Two large observational studies of patients with SpA did not suggest increased malignancy risk with patients on TNFi. 164, 165 Data on the use of biologics in renal failure are limited. However, antibodies are not excreted by the kidney. No adverse events were noted in case reports on the use of TNFi in end-stage renal failure patients with SpA. 167, 168 In addition, several case reports of chronic inflammatory or rheumatic diseases described use of tofacitinib and ustekinumab in renal failure without any adverse events. 172, 173 The panel judged the overall quality of evidence to be very low.
Thus, the members agreed that the use of TNFi in special situations such as pregnancy, lactation, renal failure and in those with a history of previous malignancy, should be cautiously undertaken and individualized for each case.
13. We strongly recommend reviewing the vaccination status of patients with axial SpA, following local guidelines (Vote 93% agreement; not graded).
Supporting statements
• Vaccination should be undertaken prior to initiating bDMARD (Not graded).
• During bDMARD therapy, live attenuated vaccines are contraindicated. Pneumococcal and influenza vaccines are recommended.
Vaccines for HBV, human papilloma virus (HPV) and meningococcal infections are conditionally recommended (Not graded).
There is some concern about the host immune response post-vaccination for patients with an immunosuppressive disease or who will potentially need medication that may compromise the immune response, such as bDMARDs. In concordance with available guidelines, the group recommends that vaccination status should be assessed in the initial work-up of patients with axial SpA, according to each country's national guidelines.
14. We conditionally recommend total hip arthroplasty in patients with refractory pain or disability and radiographic evidence of ACR/SPARTAN/SAA and ASAS/EULAR have recommended surgery for hip involvement that severely impacts mobility and quality of life. They further recommended surgical consultation in patients with refractory pain or disability and radiographic evidence of structural damage, based on low-quality evidence from observational studies and case series. 18, 19 The working group agreed that lack of high-quality evidence was not necessarily evidence of lack of efficacy, and decided to provide a recommendation that echoed current guidelines.
The group's discussions emphasized the importance of routine assessment of spinal compression fractures; and that if a patient with axial SpA were to undergo a surgical procedure, optimum preoperative care
should include temporary discontinuation of biologic therapy. 
| D ISCUSS I ON
| Use of the GRADE approach
The group used the GRADE approach to make judgements about the quality of evidence found via the literature search and to determine the strength of each final recommendation. The GRADE approach is now the international standard for assessing the quality of evidence and strength of recommendations of clinical practice guidelines (CPGs).
GRADE was initially developed by an international panel of method-
ologists who considered clinical questions on diagnosis, screening, prevention, and therapy, making it applicable for use in a wide range of health-related fields. The GRADE approach provides a systematic process of evaluating evidence, requiring the reviewer to explicitly state his or her judgment on the quality of evidence for each outcome critical to decision-making. The GRADE approach also explicitly incorporates the quality of evidence, the balance between benefit, harm and costs, and values and preferences in the final recommendations.
Through the GRADE method, the panel reviewed the evidence across studies and developed summary-of-evidence tables. These tables proved invaluable to members of the working group, who referred to them during discussions and while drafting and refining recommendations.
| Expert guidance on issues for which evidence is lacking
Some clinical questions were not directly addressed because relevant evidence to inform a strong recommendation were not identified, including questions on the use of csDMARDs, adjustment or tailoring of NSAID and bDMARD treatment, vaccination, and surgery. Rather than forego stating a recommendation, the working group recognized the need for practical guidance in these clinical situations. Recommendations were proposed by consensus, to provide reasonable advice on therapy. Areas where current evidence is lacking may be addressed in future updates to this consensus document as new information and new therapies become available. The group deems these topics to be important foci of future research, and enjoins APLAR to consider devoting resources to generating evidence-based answers to these research questions.
| Treatment-access considerations
In the Asia-Pacific region, there are some differences in genetic predisposition, disease subtypes and clinical features of SpA associated with certain ethnicities; 189, 190 nonetheless, in general, clinical features, HLA-B27 association and management of SpA are similar comparing Asia and other regions of the world. 53, 192, 193 Asian physicians regard non-pharmacological management such as physical therapy as important as pharmacological treatment, the cornerstone of which is NSAIDs. 193 Importantly, the use of TNFi, which have been reported to be effective in Asians, mainly in studies of Chinese patients, 194, 195 is increasing with the availability of cheaper biosimilar TNFi. However, the high cost of branded and (even less costly) biosimilar TNFi make them relatively inaccessible to many patients in the region, compelling clinicians to utilize less expensive alternatives. 189, 192, 193, 197 Recommendations 4 (on short-term use of corticosteroids) and 5
(on use of csDMARDs) were formulated in recognition of treatment-access limitations in the many resource-poor settings across the region.
| Soliciting patient feedback
Important to the optimal management of axial SpA is the patient-clinician partnership. The group plans to obtain patients' perspectives on these recommendations through the methodology employed by Dr Andrew Harrison and colleagues for the Patient Opinion RealTime Anonymous Liaison System (PORTAL) project for RA. 198 The PORTAL project was set up in 2014; it deployed multiple short, patient-directed surveys to elicit patients' values and preferences in relation to RA management. The group will utilize this approach for axial SpA, to include contributions of patients from the Asia-Pacific for future updates of these recommendations.
| CON CLUS ION
This document provides an up-to-date guide for treatment of axial SpA to meet the needs of patients and clinicians in the Asia-Pacific region. Clinicians implementing these current recommendations will need to consider both the individual needs and values of their patients, and the differences in each country's practice setting. 
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